• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Cost analysis of combination vs single dosage lipid-lowering

News
Article

A study was conducted to determine the cost and patient adher- ence rates of lipid-lowering therapy with an extended-release niacin and lovastatin (ERNL) combination agent versus a separate extended-release niacin and statin (ERN-S) combination or statin monotherapy.

METHODS The study methods were as follows:

CONCLUSIONS

Editors' Note: This study was originally presented as a poster at the Academy of Managed Care Pharmacy (AMCP) Educational Conference, October 13–16, 2004, in Baltimore, Md.

Dr LaFleur is an outcomes fellow at the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy, Salt Lake City, Utah. Dr LaFleur can be reached at joanne.lafleur@pharm.utah.edu
. Mr Thompson is a research assistant at the Department of Family and Preventive Medicine, School of Public Health, University of Utah. Dr Ho is a Medco Outcomes fellow at the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy. Mr Stockdale is a research assistant professor in the Pharmacotherapy Outcomes Research Center, University of Utah. Dr Charland is associate director of Health Economics and Outcomes, Kos Pharmaceuticals, and an adjunct associate professor at the University of Colorado in Denver, Colo. Dr Oderda is director of the Pharmacotherapy Outcomes Research Center and a professor at the University of Utah College of Pharmacy. Dr Brixner is an associate professor and chair of the Department of Pharmacotherapy at the University of Utah and executive director of the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy.

REFERENCES 1. Blandford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Managed Care Pharm. 1999;5:47–51.

2. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–461.

3. Diggle PJ, Heagerty P, Liang KY, Zeger SJ. Analysis of Longitudinal Data. 2nd ed. Oxford, England: Oxford University Press; 2002.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.